A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma

Prior treatment

• Patients for whom the investigator deems that irinotecan and temozolomide are not appropriate are not eligible.

Other illness

• Patients who have an uncontrolled infection are not eligible.
• Patients with known hypersensitivity to irinotecan or its excipients are not eligible.

Lab values

• Patients who have a history of Torsades de Pointes, carry a diagnosis of congestive heart failure, or have a family history of prolonged QT syndrome are not eligible.

Other

• Patients who are pregnant or breast feeding are not eligible.
• Patients who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study are not eligible.

• Consent/Assent: all patients and/or their parents or legally authorized representatives must sign written informed consent; assent, when appropriate, will be obtained according to institutional guidelines
• Age: patients must be ≥12 months of age at the time of study enrollment
• Diagnosis: patients must have histologically documented locally advanced or metastatic desmoplastic small round cell tumor or rhabdomyosarcoma (confirmed at MSK)
• Therapeutic options: patient's current disease state must be one which has failed standard therapy and for which there is no known curative therapy
• Disease Status: patients must have measurable disease based on RECIST 1.1
• Performance level: Karnofsky ≥ 50% for patients \> 16 years of age and Lansky ≥ 50 for patients ≤ 16 years of age
• Prior Therapy: patients may have had any number of prior therapies, but must have recovered from the acute toxic effects of all prior anti-cancer therapy (other than alopecia) as described below and must meet the following minimum duration from prior anti-cancer directed therapy prior to enrollment
  • °patients who have previously received irinotecan and/or temozolomide will be allowed
  • 21 days must have elapsed after the last dose of cytotoxic or myelosuppressive chemotherapy
  • 7 days must have elapsed after the last dose of anti-cancer agents not known to be myelosuppressive
  • 14 days must have elapsed after radiation therapy, and toxicity related to prior radiation therapy must be recovered to grade ≤ 1
  • 21 days must have elapsed after the last dose of antibody therapy, and toxicity related to prior antibody therapy must be recovered to grade ≤ 1
• Organ Function Requirements: Adequate bone marrow function defined as:
  • absolute neutrophil count (ANC) ≥ 1500/mm\^3
  • platelet count ≥ 100,000/ mm\^3
  • hemoglobin ≥ 8 g/dl
• Adequate renal function defined as:
  • Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min/1.73m2 OR
  • Serum creatinine based on age/gender derived from the Schwartz formula for estimating GFR53
• Adequate liver function defined as:
  • Bilirubin (sum of conjugated + unconjugated) ≤ 1.5 x upper limit of normal for age
  • AST or ALT ≤ 5 x upper limit of normal for patients with liver metastases
  • Serum albumin ≥ 2.5 g/dl
• Adequate cardiac function defined as:
  • echocardiogram with left ventricular ejection fraction (LVEF) \>45%
  • QTc \< 470 ms on screening 12 lead electrocardiogram
• Pregnancy/Contraception
  • post-menarchal females must have a negative urine or serum pregnancy test at screening and ≤ 24 hours prior to study treatment
  • males or females of reproductive potential must be willing to use a barrier method of contraception throughout the course of the study and for 6 months after participation